Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium bromide in COPD airWays clinical Study 2 (GLOW2) evaluated the efficacy and safety of NVA237 in moderate-to-severe COPD over 52...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerwin, Edward, Hébert, Jacques, Gallagher, Nicola, Martin, Carmen, Overend, Tim, Alagappan, Vijay K.T., Lu, Yimeng, Banerji, Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485572/
https://www.ncbi.nlm.nih.gov/pubmed/23060624
http://dx.doi.org/10.1183/09031936.00040712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485572/
https://www.ncbi.nlm.nih.gov/pubmed/23060624
http://dx.doi.org/10.1183/09031936.00040712

Ejemplares similares